Objective: There has been concern about the usage of aprotinin, an antifibrinolytic drug that was often used in pediatric cardiac surgery until 2006. At our center, these concerns led to the replacement of aprotinin with tranexamic acid for antifibrinolytic treatment. Methods: In this retrospective observational study, two groups of pediatric patients were studied during two different periods, receiving either aprotinin (n = 70) or tranexamic acid (n = 70) upon cardiac surgery. Data were collected from children with cyanotic heart defects, children who weighed less than 10 kg, and children who underwent re-operation. Results: There was no difference in terms of blood loss or amount of erythrocyte concentrates and fresh frozen plasma transfused. Only the intraoperative amount of platelet concentrate received by children in the tranexamic acid group was 29 ml ( p = 0.013) higher. There was no significant difference in the length of stay at the intensive care unit, in renal function values, or in the rate of rethoracotomy. Conclusions: The results of this study suggest that tranexamic acid represents an adequate alternative to aprotinin in congenital cardiac surgery. #
Introduction
Children with congenital heart disease who undergo openheart surgery often exhibit coagulation disturbances that may lead to intra-and postoperative loss of blood [1] . As transfusion of homologous blood components is associated with infectious and immunologic risks as well as increased mortality, blood-saving strategies are essential to reduce the amount of homologous blood used. For a long time, aprotinin was the standard antifibrinolytic drug in pediatric cardiac surgery. Many studies, particularly in the field of adult surgery, were able to show that the perioperative loss of blood, and thus the use of homologous blood, could be curtailed if aprotinin was administered. In 2006, the publication of a retrospective study carried out by Managno et al., in which considerable safety concerns were expressed regarding aprotinin, resulted in rethinking about its clinical use [2] . The study showed an association between the use of aprotinin and an increase in renal failure, heart attack, and stroke. These results prompted an alteration in the clinical standards of antifibrinolytic therapy at our center. From April 2006 on, all children undergoing congenital heart surgery received tranexamic acid instead of aprotinin.
So far, the use of tranexamic acid in this distinctive group of patients has not been thoroughly examined. Besides, few studies have compared the effectiveness of tranexamic acid with that of aprotinin in congenital heart surgery.
This study compares these antifibrinolytic strategies used in children with congenital heart defects, relating to their blood-saving effects as well as safety aspects.
Material and methods
The data used in this retrospective study were collected at our center during two different periods. Before and during the preoperative consultation, the parents of the children were requested for permission to use the perioperative data for scientific purposes. The Ethics Commission was not consulted given the retrospective character of the study.
The aprotinin group included patients who underwent surgery between March 2005 and June 2005. During this period, aprotinin was routinely used. The tranexamic acid group was comprised of children operated upon between April and September 2006. From then onwards, all patients were treated exclusively with tranexamic acid. In both groups we selected patients who weighed less than 10 kg, presented with cyanotic cardiac defects or underwent chest re-entry.
Different doses of aprotinin were administered, 45 000 IU kg À1 prior to cardiopulmonary bypass (CPB), 600 000 IU kg À1 during CPB and 45 000 IU kg À1 thereafter until chest closure.
Tranexamic acid was given as a bolus of 100 mg kg
À1
followed by continuous infusion of 10 mg kg À1 h À1 , as advocated by Reid et al. [3] and Sethna et al. [4] .
All other parameters that may influence the perioperative management, in particular anesthesia and CPB course, were not modified during the two periods under review. All patients in both groups were operated upon by a surgical team of three surgeons. The data were compiled from patient files by a study assistant. The following laboratory parameters were measured preoperatively, immediately after surgery and 24 h later: partial thromboplastin time (PTT), Quick, fibrinogen, platelets account and serum creatinine. The transfusion amounts of erythrocyte concentrate, fresh frozen plasma (FFP) and platelets were determined for the operative period and the first 48 postoperative hours. Blood loss via the drains was defined as the amount of blood lost via the thoracic drains 48 h after surgery. At that time, there was no specific protocol for the transfusion of homologous blood components; their use was left to the judgment of the physician in charge. Cases of rethoracotomy within the first 48 postoperative hours were excluded from the study. Aristotle score (basic and comprehensive) [5] was used to compare the complexity of procedures between the two antifibrinolytic therapy groups.
Chi-square and Fisher's test were used for univariate analysis. Mann-Whitney's test was run to compare different variables (GraphPad Prism software, San Diego, CA, USA).
Lower and upper 95% confidence intervals of mean were also computed for the most important differences. The significance level was set for a p-value of 0.05.
Results
There was no difference between the groups that received either tranexamic acid or aprotinin with regard to age and sex ( Table 1 ). The complexity of procedures was similar according to the Aristotle scores (Table 2) . Significantly higher preoperative values of fibrinogen, Antithrombin III and platelets (Table 1) were found in the aprotinin group. However the levels of these variables in the group treated with tranexamic acid remain, on the whole, within normal range.
Of the perioperative times, only the duration of cardioplegic cardiac arrest was significantly longer in the group treated with tranexamic acid (Table 2) .
When considering the intraoperative requirements for blood products, no significant difference was found in the amount of erythrocyte concentrate or in the amount of FFP transfused. The number of patients needing treatment with erythrocyte concentrates or FFP did not differ significantly either. A significant difference was found in the amount of platelet concentrate transfused. Although fewer patients in the tranexamic acid group were administered platelet concentrates, the amount of platelet concentrate administered in the tranexamic acid group was 29 ml higher, on average. There was no significant variation in postoperative blood loss (Table 3) . Similarly, no statistical difference was observed in the amounts of erythrocyte concentrate, FFP, and platelet concentrate transfused. Renal function, at least according to the serum creatinine values, was similar in the two groups. Postoperative coagulation parameters were notable for the increased PTT values in the aprotinin group (Table 4) . These values stabilized with time, but were still significantly higher 24 h after intervention, as compared to the tranexamic acid group.
Both the duration of mechanical ventilation and the length of the stay at the intensive care unit were longer in the tranexamic acid group, but the significance level was not reached (Table 3 ). There were two postoperative deaths in the aprotinin group and one in the tranexamic group, an early mortality which did not yield a significant difference. The number of re-operations did not differ between the two groups. In the aprotinin group, the two re-operations due to thrombosis complication were not statistically relevant.
The subgroup of children aged less than 2 months was analyzed separately. Table 5 shows that patients in the tranexamic acid group received a larger amount of platelet concentrate. But no difference was found in the postoperative transfusion amounts of erythrocyte concentrate, platelet concentrate, and FFP. There was just a significantly higher number of patients in the aprotinin group that received FFP postoperatively.
Discussion
Complex neonatal cardiac surgery, repair of cyanotic defects, and rethoracotomies constitute the three reported indications for antifibrinolytics drugs toward reducing the consumption of blood products after congenital open-heart surgery [6] [7] [8] . In this study, aprotinin and tranexamic acid were used for patients weighing less than 10 kg, having cyanotic cardiac defects or submitted to a chest re-entry procedure. As the license for aprotinin has been withdrawn in Germany in 2007, the assessment of other antifibrinolytic substances available there such as tranexamic acid is essential.
In our series, the use of tranexamic acid and aprotinin led to overall comparable consumption of blood products. Interestingly, the number of patients that required platelet concentrates perioperatively is significantly lower in the tranexamic acid group ( p = 0.04). However, the average amount of platelet concentrate transfused is greater. The supposition that -intraoperative and postoperative phases combined -a significantly lower number of patients in the tranexamic acid group were treated with platelet concentrates was not confirmed. During the entire study period, 25 patients in the aprotinin group and 22 patients in the tranexamic acid group received platelet concentrates.
As one examines the coagulation parameters in the aprotinin group, the slightly higher fibrinogen values observed immediately after surgery (Table 4) could be explained by higher preoperative initial values (Table 1) . Strikingly, the PTT values in the same group increased very significantly during the first 24 h after surgery ( Table 4 ). The postoperative Quick values were similar in the tranexamic acid and aprotinin groups, and the values had almost normalized 24 h after surgery (Table 4) . Therefore the increase in PTT values could be interpreted as being the result of the prolonged effects of heparin.
In our separate analysis of children under 2 months of age, again the two study groups showed no difference in the amount of erythrocyte concentrate, platelet concentrate, or FFP transfused postoperatively (Table 5) .
These findings allow us to support that aprotinin can be replaced with the antifibrinolytic agent tranexamic acid with no rise in blood loss or relevant increments in the amount of blood products used. Bulutcu et al. [8] reached the same conclusion. A recently published observational study nonetheless found aprotinin to be more effective [9] .
There were two deaths in the aprotinin group and one death in the tranexamic acid group. This does not represent a significant variation. There was no evidence of alteration in the creatinine values. In our study, the fact that no connection was found between aprotinin and end points such as a higher mortality rate and renal failure might be due to the small number of patients. With a low number of patients the statistical power is insufficient to effectively detect relatively rare events. Fergusson states that for aprotinin, the 'number needed to harm' is 50. However, the most recent study on the safety of aprotinin with a large number of patients (n = 30 372) did not show increased mortality or dialysis in children undergoing congenital heart operations [10] .
Breuer et al. found an increase (albeit not statistically significant) in the number of seizures in patients treated with tranexamic acid [9] . Similar findings are available from adult cardiac surgery as well as neurosurgery patients [11] . Indeed, these data show an association between the use of tranexamic acid and epileptic seizures. This can be explained by the antagonistic effect of tranexamic acid on gaminobutyric acid (GABA) receptors [12] . To what extent this affects end points such as cerebral ischemia or mortality has yet to be examined. However, this demonstrates the importance, in the 'post-aprotinin era', of arousing interest in the safety aspects of other antifibrinolytic alternatives.
The use of antifibrinolytics always interferes with the natural balance of pro-and anticoagulatory forces. There are justifiable fears that inhibition of fibrinolysis may lead to a thrombotic event. In children with cyanotic defects, activation of fibrinolysis can already be observed in the preoperative period. It is difficult to say how often thromboses occur under antifibrinolytic therapy in pediatric cardiac surgery. For aprotinin and tranexamic acid, reports are chiefly episodic [13] . In this respect, whether tranexamic acid offers an advantage over aprotinin, which is also said to have anticoagulatory characteristics, has not been sufficiently examined. In a study by Jaquiss et al. [14] , no thrombotic events were observed in 865 children that underwent cardiac surgery with aprotinin therapy. Considering an estimated 20% incidence of thrombosis in the area of the central venous catheter in pediatric cardiac surgery, one would assume that thrombotic events are probably underdiagnosed. In our study, two patients from the aprotinin group required rethoracotomy following thrombosis, but no significant difference with the tranexamic acid group could be derived. However, there was no control group for comparison.
At this point, it is definitely of interest to discuss what dose of tranexamic acid should be given to achieve the desired result and avoid side effects. The dose of tranexamic acid used in our study ensures an adequate plasma level.
Study limitations
Treatment with either aprotinin or tranexamic acid was not compared with a control group. Therefore, the extent to which these drugs were effective cannot be determined. Appraising the value of our results, the fact that all patients were operated on in one center over an easily assessable period of 9 months by the same surgical team, stands as a positive feature in the design of the study. Another advantage is the restriction to one antifibrinolytic substance in each of the periods under review. The standardized selection criteria warranted comparable groups, as substantiated by the similar Aristotle score in both groups.
The retrospective character of this study naturally impedes inference of possible causalities. Alterations and improvements in the surgical procedures and perioperative environment between the two periods can obviously not be ruled out. The significant increase in the 'surgical performance' score for the tranexamic acid group, with a non-significant variation between the 'basic' and 'comprehensive Aristotle score' (Table 2) , can be explained by the lower average mortality in this period. This may serve as evidence of improved operative and perioperative procedures, particularly in respect to surgery. To argue the converse, that the change from aprotinin to tranexamic acid is responsible for this development, would be improper.
Conclusions
The data in this retrospective study provide further evidence that the antifibrinolytic substance aprotinin may be replaced with tranexamic acid in the field of congenital cardiac surgery with comparable effectiveness. The results of this study raise no consistent concerns regarding the safety of aprotinin or tranexamic acid. In countries where aprotinin is no longer allowed, the safety of use of tranexamic acid should become a prime focus. Evidence accumulated from the field of congenital cardiac surgery, including the information gained in this study, is still insufficient to clearly estimate the benefits and risks associated with the use of tranexamic acid.
